The bicyclam AMD3100 story

E De Clercq - Nature reviews Drug discovery, 2003 - nature.com
E De Clercq
Nature reviews Drug discovery, 2003nature.com
The discovery and development of the bicyclam AMD3100—a chemokine receptor
antagonist—has highlighted the therapeutic potential of such compounds in HIV infection,
inflammatory diseases, cancer and stem-cell mobilization. Here, I describe the development
process of AMD3100, which began about 15 years ago with the isolation of an impurity, and
the basis for the clinical application of AMD3100 and its congeners.
Abstract
The discovery and development of the bicyclam AMD3100 — a chemokine receptor antagonist — has highlighted the therapeutic potential of such compounds in HIV infection, inflammatory diseases, cancer and stem-cell mobilization. Here, I describe the development process of AMD3100, which began about 15 years ago with the isolation of an impurity, and the basis for the clinical application of AMD3100 and its congeners.
nature.com